Menu Search
Equities

Ligand Pharmaceuticals Inc

LGDN:BER

Ligand Pharmaceuticals Inc

Actions
  • Price (EUR)119.00
  • Today's Change10.00 / 9.17%
  • Shares traded30.00
  • 1 Year change+139.92%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

  • Revenue in USD (TTM)133.48m
  • Net income in USD42.14m
  • Incorporated1987
  • Employees58.00
  • Location
    Ligand Pharmaceuticals Inc3911 Sorrento Valley Blvd, Suite 110SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 550-7500
  • Fax+1 (302) 636-5454
  • Websitehttps://www.ligand.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.